Introduction
Cardiovascular disease becomes increasingly prevalent with advancing age, while its clinical expression and management become progressively more complex. Older adults, often defined in cardiovascular practice as those older than 75 years, are not a homogeneous population: biological age, frailty, multimorbidity, sarcopenia, cognitive function, functional capacity, and health-related quality of life substantially influence both cardiovascular risk and the balance between treatment benefit and harm.
Prevention in the very elderly therefore extends beyond reducing myocardial infarction, stroke, heart failure, or cardiovascular death. Preservation of mobility, cognition, independence, functional capacity, and quality of life may be equally important therapeutic objectives. Evidence from randomized trials is often less applicable to very frail or multimorbid patients because these groups have historically been underrepresented. Consequently, prevention requires individualized assessment, careful monitoring, and shared decision-making.
Definition and Pathophysiology
Aging-related cardiovascular vulnerability
Normal aging produces structural and functional cardiovascular changes that increase susceptibility to disease. Cellular atrophy, myocardial fibrosis, calcification, vascular remodeling, altered diastolic filling, chronotropic incompetence, and impaired hemodynamic stability commonly coexist. These changes promote hypertension, ischemia, valvular abnormalities, arrhythmias, and heart failure.
Aging also accumulates conventional cardiovascular risk factors, including hypertension, diabetes, hypercholesterolemia, smoking exposure, and physical inactivity. The interaction between these acquired risks and age-related cardiovascular remodeling contributes to the high incidence and prevalence of coronary and vascular disease in older adults.
Geriatric syndromes further modify cardiovascular risk and treatment response. Multimorbidity, frailty, sarcopenia, cognitive impairment, and reduced physiologic reserve may dominate clinical outcomes and limit tolerance of otherwise evidence-based interventions.
Hypertension and vascular disease
Hypertension is the most common modifiable cardiovascular risk factor in older adults. It contributes to vascular injury, accelerates atherosclerosis, increases myocardial oxygen demand, and may worsen ischemia in patients with obstructive coronary disease. It is also the most prevalent antecedent of heart failure—particularly heart failure with preserved ejection fraction—and chronic kidney disease.
After approximately 70 years of age, isolated systolic hypertension accounts for more than 90% of prevalent hypertension. Hypertension has a major population-attributable contribution to chronic coronary disease, cerebrovascular disease, and peripheral arterial disease. More than 70% of older adults presenting with myocardial infarction, stroke, acute aortic syndromes, or heart failure have preexisting hypertension.
The relationship between blood pressure and outcome in older adults is not linear at very low pressures. Excessive reduction in diastolic blood pressure may compromise coronary perfusion, particularly in patients with coronary disease. Excessive systolic reduction may be associated with falls, syncope, renal deterioration, functional decline, and cognitive impairment.
Heart failure
Heart failure represents a major intersection between cardiovascular disease and geriatric medicine. Its incidence and prevalence rise steeply with age, reflecting accumulated risk factors, age-related reduction in cardiovascular reserve, and the increasing burden of comorbid disease.
Heart failure with preserved ejection fraction becomes particularly common among the very old. Hypertension, diabetes, atrial fibrillation, and age-related changes in left ventricular filling contribute to susceptibility. Heart failure with preserved ejection fraction is regarded as a multifactorial systemic illness involving aging-related processes rather than solely an isolated abnormality of diastolic function.
Clinical Presentation and Symptoms
Older adults may present with conventional cardiovascular symptoms, but atypical manifestations are frequent and may delay diagnosis.
In chronic coronary disease, older patients may have symptoms other than typical angina. Reduced exertional activity, mobility limitation, cognitive impairment, or multiple comorbidities may obscure the relationship between exertion and symptoms.
Heart failure commonly causes dyspnea and fatigue, but older patients are more likely to present with altered mental status, depression, or impaired executive functioning. These manifestations may be mistaken for primary neurologic, psychiatric, or functional disorders.
The clinical consequences of cardiovascular disease may also appear as loss of independence, reduced exercise tolerance, recurrent falls, worsening mobility, or decline in cognition. Such outcomes should be incorporated into preventive assessment because they may represent the patient’s most important health priorities.
Evaluation and Physical Examination
Comprehensive geriatric-cardiovascular assessment
Assessment should extend beyond conventional cardiovascular risk estimation. Relevant domains include:
Frailty and sarcopenia
Functional capacity and mobility
Cognitive function
Multimorbidity
Orthostatic symptoms and blood-pressure regulation
Medication burden and treatment-related adverse effects
Renal function
Patient-defined goals, priorities, and expected lifespan
Health-related quality of life and independence
Frailty screening using validated clinical tests should be considered, particularly when treatment intensity or blood-pressure targets are uncertain. The degree of frailty is important because the safety and efficacy of preventive treatment are less certain in patients with moderate or severe frailty.
Blood-pressure assessment
Blood pressure should be assessed with attention to orthostatic symptoms and tolerance of therapy. Age-related blunting of baroreceptor function and orthostatic dysregulation may increase vulnerability to postural hypotension.
In patients with coronary disease and evidence of myocardial ischemia, blood pressure should be reduced gradually. Diastolic blood pressure below 60 mm Hg should be avoided in elderly patients with coronary disease when possible. Overly aggressive systolic reduction, particularly below 110 mm Hg, should also be avoided in older adults at risk of falls, syncope, renal dysfunction, functional decline, or cognitive impairment.
Medication and treatment-burden assessment
Polypharmacy is common in older adults and may become excessive when multimorbidity and frailty coexist. The assessment should consider cumulative hypotensive effects, bradycardia, bleeding risk, renal adverse effects, electrolyte abnormalities, constipation, edema, incontinence, fatigue, and reduced physical activity.
If blood pressure falls as frailty progresses, deprescribing antihypertensive therapy may be appropriate. Other drugs that lower blood pressure, including sedatives and prostate-specific alpha-blockers, should also be reviewed.
Diagnostics
The source material emphasizes clinical assessment, blood-pressure evaluation, frailty assessment, and the use of noninvasive testing to identify ischemia in patients with chronic coronary disease. It does not provide specific recommendations regarding electrocardiography, laboratory-based cardiovascular risk assessment, echocardiographic protocols, ambulatory blood-pressure monitoring, or other diagnostic modalities for primary prevention in the very elderly.
In chronic coronary disease, coronary angiography and revascularization are recommended for older adults with refractory symptoms, particularly when noninvasive diagnostic testing demonstrates significant ischemia. Decisions regarding invasive evaluation should account for frailty, comorbidities, functional capacity, procedural risk, and patient preferences.
Biomarkers and Laboratory Findings
The source material does not specify biomarker thresholds, laboratory diagnostic criteria, or laboratory surveillance protocols for cardiovascular prevention in the very elderly.
Renal function and potassium are clinically important during treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers because older adults are vulnerable to impaired renal function and hyperkalemia. Monitoring treatment tolerance is especially important in very old and frail patients.
Prevention Strategies
Lifestyle and nonpharmacologic intervention
Nonpharmacologic treatment is recommended as initial therapy for mild hypertension and can reduce the risks associated with polypharmacy. Measures include:
Aerobic exercise and regular physical activity
Reduction of excess body weight
Reduction of psychological stress
Limitation of sodium and alcohol intake
Smoking cessation
Treatment of sleep apnea when present
Adoption of the Dietary Approaches to Stop Hypertension eating plan
Healthy sleep
Management of blood glucose and cholesterol
Regular exercise improves aerobic capacity and has favorable effects on blood pressure, lipids, glucose tolerance, bone density, and depression. It also helps preserve independent living and is the only intervention identified in the source material as capable of preventing or reversing sarcopenia. Even moderate or low levels of activity, such as walking for 30 minutes daily, have protective effects in obese individuals.
In frail older adults, supervised muscle-strengthening physiotherapy and supervised exercise with coordination and balance training may help address reversible contributors to frailty.
Blood-pressure targets
Blood-pressure targets should be individualized according to age, frailty, symptoms, comorbidity, treatment tolerance, and patient priorities.
For very old and frail patients, the available clinical-trial evidence has not demonstrated loss of benefit from blood-pressure reduction among the relatively mildly frail populations included in trials. However, generalization to patients with significant frailty or multimorbidity remains uncertain. Current recommendations support treatment toward 120–129/70–79 mm Hg in very old and frail patients when treatment is tolerated, while emphasizing personalized decision-making.
In older adults with chronic coronary disease, a target below 130/80 mm Hg is recommended in the source material, but blood pressure should be lowered slowly and excessive diastolic reduction avoided.
Lipid and cholesterol management
Moderate- and high-intensity statins are recommended for adults older than 75 years. Higher doses may increase the risks of myalgia, fatigue, and reduced physical activity. The decision to initiate or continue statin therapy should therefore consider treatment tolerance, frailty, functional status, competing illnesses, and patient priorities.
The source material identifies cholesterol control as a core component of cardiovascular prevention but does not provide specific low-density lipoprotein cholesterol targets or dosing regimens.
Smoking, weight, diabetes, and sleep
Smoking cessation, weight management, healthy eating, physical activity, and management of blood glucose are identified as core prevention measures. Sleep apnea should be treated when present, and adequate sleep is included among the broader health measures supporting cardiovascular health in older adults.
Pharmacologic Treatment
Antihypertensive therapy
Recommended first-line antihypertensive classes are:
Diuretics
Angiotensin-converting enzyme inhibitors
Angiotensin receptor blockers
Calcium channel blockers
Beta-blockers are not considered first-line antihypertensive therapy in the absence of another compelling indication, despite their frequent use.
Approximately two-thirds of older adults with hypertension require two or more agents to reach target blood pressure. Combination therapy may permit lower doses of individual drugs, reduce dose-dependent adverse effects, extend the duration of action, and provide additive target-organ protection.
Treatment should generally begin at low doses with gradual upward titration because age-related pharmacokinetic and pharmacodynamic changes increase susceptibility to adverse effects and orthostatic hypotension.
Treatment in patients aged ≥85 years or with moderate-to-severe frailty
For patients aged at least 85 years or those with moderate-to-severe frailty at any age, long-acting dihydropyridine calcium channel blockers or renin–angiotensin-system inhibitors should be considered initially. If required and tolerated, a low-dose diuretic may be added. Beta-blockers should generally be avoided for blood-pressure treatment unless a compelling indication exists, and alpha-blockers are not preferred.
Blood-pressure treatment should be considered from ≥140/90 mm Hg in patients with symptomatic orthostatic hypotension before treatment, age ≥85 years, clinically significant moderate-to-severe frailty, or a predicted lifespan of less than three years, with close monitoring of tolerance.
If blood pressure falls as frailty progresses, deprescribing may be considered.
Adverse effects relevant to older adults
Older adults have increased susceptibility to medication-related harm. Important adverse effects include:
| Drug class | Important adverse effects in older adults |
|---|---|
| Aspirin and other antithrombotic agents | Bleeding |
| Beta-blockers | Bradycardia and hypotension |
| Calcium channel blockers | Bradycardia, hypotension, pedal edema, constipation, and incontinence, depending on the agent |
| ACE inhibitors and ARBs | Impaired renal function and hyperkalemia |
| Nitrates | Postural hypotension |
| Higher-dose statins | Myalgia, fatigue, and reduced physical activity |
Heart-failure therapy
The therapeutic approach to heart failure with reduced ejection fraction should, in principle, follow the same pharmacologic strategy as in younger adults. However, reduced renal function, altered drug handling, impaired baroreceptor responses, and orthostatic dysregulation may require more cautious application and dose reduction when appropriate. These factors may limit attainment of target doses of neurohormonal antagonists.
Multidisciplinary heart-failure programs have reduced readmissions and associated morbidity in elderly patients.
Revascularization and Chronic Coronary Disease
Management of chronic coronary disease in older adults includes risk-factor control, symptom relief, and prevention of myocardial infarction and death.
Coronary angiography and revascularization should be considered in patients with refractory symptoms, particularly when noninvasive testing shows significant ischemia. In older adults with persistent angina despite at least two antianginal drugs, revascularization has been associated with better symptom relief and exercise capacity than optimized medical therapy alone. Revascularization also improves quality of life in patients with a high symptom burden.
Percutaneous coronary intervention carries somewhat higher procedural risks in older adults, including bleeding, stroke, and contrast-associated kidney injury. Bleeding risk can be reduced by:
Using radial rather than femoral access when appropriate
Adjusting anticoagulant and antiplatelet doses according to body weight and renal function
Using shorter durations of dual antiplatelet therapy after percutaneous coronary intervention when clinically appropriate
Short-term dual antiplatelet therapy after percutaneous coronary intervention reduces major bleeding without increasing cardiovascular events compared with longer treatment durations in the evidence summarized. In patients who also require chronic anticoagulation, stopping aspirin while continuing a P2Y12 inhibitor is associated with less bleeding.
Drug-eluting stents combined with short-duration dual antiplatelet therapy have safety and efficacy advantages over bare-metal stents in older adults.
The choice between percutaneous coronary intervention and coronary artery bypass grafting should incorporate:
Coronary anatomy
Comorbidities
Functional capacity
Frailty
Expected recovery
Patient preferences
Coronary artery bypass grafting is generally associated with less recurrent symptoms and fewer repeat revascularization procedures, but it entails a longer recovery and greater risks of atrial fibrillation and neurologic complications.
Guideline Recommendations
The principal recommendations for cardiovascular prevention in the very elderly are summarized below.
| Recommendation | Strength of recommendation | Evidence level |
|---|---|---|
| Treat elevated blood pressure and hypertension in patients younger than 85 years who are not moderately or severely frail according to the same principles used in younger adults, provided treatment is tolerated | Class I | A |
| Continue blood-pressure-lowering therapy lifelong, including beyond age 85 years, when it remains well tolerated | Class I | A |
| Consider initiating blood-pressure treatment from ≥140/90 mm Hg in patients with symptomatic orthostatic hypotension before treatment, age ≥85 years, moderate-to-severe frailty, or predicted lifespan below three years; monitor tolerance closely | Class IIa | B |
| Screen older adults for frailty when treatment safety and targets are uncertain, and incorporate health priorities and shared decision-making | Class IIa | C |
| In patients aged ≥85 years or with moderate-to-severe frailty, consider a long-acting dihydropyridine calcium channel blocker or renin–angiotensin-system inhibitor initially, followed if needed by a low-dose diuretic; generally avoid beta-blockers unless compelling indications exist and avoid alpha-blockers | Class IIa | B |
| Consider deprescribing antihypertensive drugs, as well as other blood-pressure-lowering medications, when blood pressure falls with advancing frailty | Class IIb | C |
For patients with chronic coronary disease, blood-pressure control to less than 130/80 mm Hg is recommended, while avoiding excessive lowering of diastolic blood pressure, particularly below 60 mm Hg in elderly patients with coronary disease and ischemia.
Special Considerations in Frailty and Multimorbidity
Applicability of clinical trials
Older adults, especially those with substantial frailty or multimorbidity, are frequently underrepresented in randomized trials. The treatment effects observed in trial populations may therefore not translate directly to patients with advanced frailty, major cognitive impairment, limited life expectancy, or extensive competing illness.
Observational studies suggesting that lower blood pressure may be harmful in frail individuals are difficult to interpret because reverse causality and arterial stiffness may confound the relationship. Accordingly, treatment decisions should not rely solely on observational J-shaped associations.
Shared decision-making
Shared decision-making should balance:
Reduction of cardiovascular events
Prevention of stroke and heart failure
Symptom relief
Preservation of cognition and independence
Maintenance of mobility and functional capacity
Treatment burden
Risk of bleeding, hypotension, renal dysfunction, and other adverse effects
Life expectancy
Patient-defined goals and priorities
A disease-focused strategy may be inappropriate when it imposes substantial treatment burden without a meaningful prospect of improving outcomes that matter to the patient.
Prognosis and Follow-up
Cardiovascular risk and mortality increase substantially with age. Heart failure illustrates this relationship: prevalence rises from approximately 6% among adults aged 60–79 years to about 14% among those aged 80 years or older. Mortality rates increase markedly in octogenarians, and median survival is shorter among hospitalized patients aged 85 years or older than among younger hospitalized patients. Atrial fibrillation, lower left ventricular ejection fraction, and renal insufficiency are associated with worse long-term outcomes.
More than 60% of older Medicare beneficiaries with heart failure have at least five comorbid conditions, and increasing multimorbidity is associated with higher readmission rates and healthcare expenditure.
Follow-up should therefore assess not only blood pressure and cardiovascular events but also:
Orthostatic symptoms
Falls and syncope
Renal function and potassium when renin–angiotensin-system inhibitors are used
Bradycardia and fatigue with beta-blockers
Edema, constipation, and hypotension with calcium channel blockers
Bleeding with antithrombotic therapy
Myalgia, fatigue, and reduced activity with intensive statin therapy
Mobility, sarcopenia, cognition, and functional independence
Medication burden and opportunities for deprescribing
Treatment adherence and continuity during care transitions
Quality of life and alignment with patient priorities
Therapy should be reassessed as frailty, cognition, renal function, functional status, and life expectancy evolve. Prevention in the very elderly is best understood as a continuing process of risk reduction and goal-concordant care rather than the pursuit of a fixed treatment target at all costs.
